COVID-19
Conditions
Brief summary
Preliminarily investigate the safety and efficacy of two doses of hzVSF-v13 + SOC vs. placebo + SOC for the treatment of COVID-19 pneumonia.
Detailed description
Proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled
Interventions
DRUGhzVSF-v13
Dosage form: 100mg / 200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7, D14(if necessary)
Sponsors
ImmuneMed, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed written informed consent from any patient capable of giving consent, or, when the patient is incapable of doing so, by his or her legal/authorized representative. Note: In accordance with the European Medicines Agency (EMA) Guidance on the management of clinical trials during the covid-19 (coronavirus) pandemic version 3 28/04/2020, if written consent by the trial participant is not possible (for example because of physical isolation due to COVID-19 infection), consent may be given orally by the trial participant in the presence of an impartial witness. 2. Age 18 years or older. 3. Patient is currently hospitalized. 4. Diagnosis of COVID-19 pneumonia including a positive RT-PCR test for SARS-CoV-2 of any specimen and lung involvement confirmed with chest imaging (X-ray or computed tomography \[CT\] scan). 5. Able to comply with the study protocol. 6. Female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or must agree to use an effective method of contraception throughout the study and for up to 120 days after stopping treatment. Effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.
Exclusion criteria
1. Patients with known or suspected hypersensitivity to hzVSF-v13 or to any of its excipients. 2. Active tuberculosis or suspected active bacterial, fungal, viral, or other infection (besides COVID-19). 3. Anti-rejection or immunomodulatory drugs within the past 3 months. 4. Absolute neutrophil count (ANC) \< 1000/µL at screening. 5. Platelet count \< 50,000/ µL at screening. 6. ALT or AST \> 5 x upper limit of normal (ULN) within 24 hours at screening. 7. Serum creatinine \> 2 mg/dL (\> 176.8 μmol/L) or estimated creatinine clearance \< 30 ml/min measured or calculated by Cockroft Gault equation. 8. Pregnancy or breastfeeding. 9. Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization (approved/investigational COVID-19 antivirals and other off-label drugs recommended by local health authorities are permitted). 10. Patients who in the opinion of the treating physician should not participate in this program (ex: severe acute respiratory distress syndrome \[ARDS\], septicaemia).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical failure at Day 28 | Day 28 | A patient will be considered a clinical failure if on Day 28 the patient is dead, intubated and/or in ICU. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Improvement, defined as a decrease of at least 2 points on the World Health Organization (WHO) ordinal scale | Day 28 | Clinical improvement is defined as a decrease of at least two points on the WHO ordinal scale from the Day 1 visit to the Day 28 visit. |
| Rate of overall survival (OS) at Day 28 and Day 60 | Day 28, Day 60 | Overall survival (OS), defined as the time from randomization to the date of death due to any cause, will be analysed by means of Kaplan-Meier methodology. |
| Incidence and severity of adverse events according to NCI CTCAE v5.0 | Day 60 | The incidence of AEs will be tabulated by MedDRA System Organ Class and Preferred Term. The incidence of AEs will also be summarised by System Organ Class, Preferred Term, and severity (based on NCI CTCAE v5.0 grades) |
Countries
Italy, Russia
Outcome results
None listed